Inflammation and gastrointestinal cancer: An overview

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 153-156

  Marusawa, Hiroyuki ^a   Jenkins, Brendan John ^b  

^a KYOTO UNIVERSITY   (Japan)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Gastrointestinal cancer; Inflammation; NF B; STAT3; TLRs

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN; TOLL LIKE RECEPTOR;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC INFLAMMATION; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SURGERY; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; INNATE IMMUNITY; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SURVIVAL RATE;

GASTROINTESTINAL CANCER; INFLAMMATION; NF-ΚB; STAT3; TLRS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; NF-KAPPA B; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTORS;

EID: 84896736687     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.025     Document Type: Review

References (48)

1. Mannick E.E., Bravo L.E., Zarama G., Realpe J.L., Zhang X.J., Ruiz B., Fontham E.T., Mera R., Miller M.J., Correa P. Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res. 1996, 56:3238-3243.
2. Zhang R., Kang K.A., Kim K.C., Na S.Y., Chang W.Y., Kim G.Y., Kim H.S., Hyun J.W. Oxidative stress causes epigenetic alteration of CDX1 expression in colorectal cancer cells. Genetics 2013, 524:214-219.
3. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121:2373-2380.
4. Fox J.G., Wang T.C. Inflammation, atrophy, and gastric cancer. J. Clin. Invest. 2007, 117:60-69.
5. Chiba T., Marusawa H., Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012, 143:550-563.
6. Clemente J.C., Ursell L.K., Parfrey L.W., Knight R. The impact of the gut microbiota on human health: an integrative view. Cellular 2012, 148:1258-1270.
7. Arthur J.C., Perez-Chanona E., Mühlbauer M., Tomkovich S., Uronis J.M., Fan T.J., Campbell B.J., Abujamel T., Dogan B., Rogers A.B., Rhodes J.M., Stintzi A., Simpson K.W., Hansen J.J., Keku T.O., Fodor A.A., Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
8. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., Iwakura Y., Oshima K., Morita H., Hattori M., Honda K., Ishikawa Y., Hara E., Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
9. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
10. DiDonato J.A., Mercurio F., Karin M. NF-κB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
11. Huber M.A., Azoitei N., Baumann B., Grünert S., Sommer A., Pehamberger H., Kraut N., Beug H., Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114:569-581.
12. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Karin M.F.M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cellular 2004, 118:285-296.
13. Shimizu T., Marusawa H., Endo Y., Chiba T. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci. 2012, 103:1201-1206.
14. Marusawa H., Takai A., Chiba T. Role of activation-induced cytidine deaminase in inflammation-associated cancer development. Adv. Immunol. 2011, 111:109-141.
15. Honjo T., Kinoshita K., Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu. Rev. Immunol. 2002, 20:165-196.
16. Matsumoto Y., Marusawa H., Kinoshita K., Endo Y., Kou T., Morisawa T., Azuma T., Okazaki I.M., Honjo T., Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 2007, 13:470-476.
17. Endo Y., Marusawa H., Kinoshita K., Morisawa T., Sakurai T., Okazaki I.M., Watashi K., Shimotohno K., Honjo T., Chiba T. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogenesis 2007, 26:5587-5595.
18. Endo Y., Marusawa H., Kou T., Nakase H., Fujii S., Fujimori T., Kinoshita K., Honjo T., Chiba T. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 2008, 135:889-898. 898 e881-883.
19. Takai A., Marusawa H., Minaki Y., Watanabe T., Nakase H., Kinoshita K., Tsujimoto G., Chiba T. Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogenesis 2012, 31:1733-1742.
20. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
21. Fukata M., Hernandez Y., Conduah D., Cohen J., Chen A., Breglio K., Goo T., Hsu D., Xu R., Abreu M.T. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm. Bowel Dis. 2009, 15:997-1006.
22. Fukata M., Shang L., Santaolalla R., Sotolongo J., Pastorini C., España C., Ungaro R., Harpaz N., Cooper H.S., Elson G., Kosco-Vilbois M., Zaias J., Perez M.T., Mayer L., Vamadevan A.S., Lira S.A., Abreu M.T. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm. Bowel Dis. 2011, 17:1464-1473.
23. Tye H., Kennedy C.L., Najdovska M., McLeod L., McCormack W., Hughes N., Dev A., Sievert W., Ooi C.H., Ishikawa T.O., Oshim H., Bhathal P.S., Parker A.E., Oshima M., Tan P., Jenkins B.J. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012, 22:466-478.
24. Uno K., Kato K., Atsumi T., Suzuki T., Yoshitake J., Morita H., Ohara S., Kotake Y., Shimosegawa T., Yoshimura T. Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am. J. Phys. Gastrointest. Liver Phys. 2007, 293:1004-1012.
25. Tye H., Jenkins B.J. Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. Cancer Sci. 2013, (Epub ahead of print).
26. Slattery M.L., Herrick J.S., Bondurant K.L., Wolff R.K. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int. J. Cancer 2012, 130:2974-2980.
27. Wang X., Xue L., Yang Y., Xu L., Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One 2013, 8:e65731.
28. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
29. Kennedy C.L., Najdovska M., Tye H., McLeod L., Yu L., Jarnick A., Bhathal P.S., Putoczki T., Ernst M., Jenkins B.J. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis. Oncogene 2013, (Epub ahead of print).
30. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell-Jr J.E. Stat3 as an oncogene. Cellular 1999, 98:295-303.
31. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
32. Xi S., Gooding W.E., Grandis J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005, 24:970-979.
33. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
34. Kawada M., Seno H., Uenoyama Y., Sawabu T., Kanda N., Fukui H., Shimahara Y., Chiba T. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res. 2006, 66:2913-2917.
35. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009, 15:103-113.
36. Ernst M., Najdovska M., Grail D., Lundgren-May T., Buchert M., Tye H., Matthews V.B., Armes J., Bhathal P.S., Hughes N.R., Marcusson E.G., Karras J.G., Na S., Sedgwick J.D., Hertzog P.J., Jenkins B.J. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 2008, 118:1727-1738.
37. Mansell A., Jenkins B.J. Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. Cytokine Growth Factor Rev. 2013, 24:249-256.
38. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132:1359-1374.
39. West X.Z., Malinin N.L., Merkulova A.A., Tischenko M., Kerr B.A., Borden E.C., Podrez E.A., Salomon R.G., Byzova T.V. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nat. Med. 2010, 467:972-976.
40. 2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 2011, 140:596-607.
41. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
42. Smyth E.C., Capanu M., Janjigian Y.Y., Kelsen D.K., Coit D., Strong V.E., Shah M.A. Tobacco use is associated with increased recurrence and death from gastric cancer. Ann. Surg. Oncol. 2012, 19:2088-2094.
43. Wang X.Q., Terry P.D., Yan H. Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. World J. Gastroenterol. 2009, 15:2204-2213.
44. Vargas A.J., Thompson P.A. Diet and nutrient factors in colorectal cancer risk. Nutr. Clin. Pract. 2012, 27:613-623.
45. Zhu Y., Luo T.M., Jobin C., Young H.A. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett. 2011, 309:119-127.
46. Ooi C.H., Ivanova T., Wu J., Lee M., Tan I.B., Tao J., Ward L., Koo J.H., Gopalakrishnan V., Zhu Y., Cheng L.L., Lee J., Rha S.Y., Chung H.C., Ganesa K., So J., Soo K.C., Lim D., Chan W.H., Wong W.K., Bowtell D., Yeoh K.G., Grabsch H., Boussioutas A., Tan P. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009, 5:e1000676.
47. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy. Hopes Pitfalls, Nat. Rev. Drug Discov. 2009, 8:33-40.
48. Yue P., Turkson J. Targeting STAT3 in cancer: how successful are we. Expert Opin. Invest. Drugs 2009, 18:45-56.